Biopharma BD&L: the tsunami is upon us

Biopharma BD&L: the tsunami is upon us

Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future. As the biopharma industry navigates an increasingly complex marketplace, traditional approaches to identifying and evaluating potential drug candidates are showing signs of strain.

5 insights from JPM 2025

5 insights from JPM 2025

Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.